REGN - Regeneron Pharmaceuticals Inc. (REGN) Q1 2024 Earnings Call Transcript
2024-05-02 12:28:13 ET
Regeneron Pharmaceuticals, Inc. (REGN)
Q1 2024 Earnings Conference Call
May 02, 2024, 08:30 AM ET
Company Participants
Ryan Crowe - Senior Vice President, Investor Relations
Leonard Schleifer - Board Co-Chair, Co-Founder, President & Chief Executive Officer
George Yancopoulos - Board Co-Chair, Co-Founder, President & Chief Scientific Officer
Marion McCourt - Executive Vice President, Commercial
Chris Fenimore - Senior Vice President & Chief Financial Officer
Conference Call Participants
Colin Bristow - UBS
Evan Seigerman - BMO Capital Markets
Christopher Raymond - Piper Sandler
Salveen Richter - Goldman Sachs
Tyler Van Buren - TD Cowen
Terence Flynn - Morgan Stanley
William Pickering - Bernstein
Carter Gould - Barclays
Brian Abrahams - RBC Capital Markets
Mohit Bansal - Wells Fargo
Presentation
Operator
Welcome to the Regeneron Pharmaceuticals First Quarter 2024 Earnings Conference Call. My name is Josh, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded.
I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.
Ryan Crowe
Thanks, Josh. Good morning, good afternoon and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our first quarter 2024 earnings conference call.
An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after the call ends....
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript